Zobrazeno 1 - 10
of 61
pro vyhledávání: '"YuXu Zhong"'
Autor:
Shanshan Feng, Hailin Tan, Shuping Zhong, Jing Ji, Junhua Yuan, Yongfeng Lin, Qixuan Dong, Xiaomeng Liu, Yiwei Wang, Qingkun Wang, Ruiqi Xu, Yuxu Zhong, Qixiao Jiang
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 282, Iss , Pp 116714- (2024)
6:2 fluorotelomer carboxylic acid (6:2 FTCA) is a perfluorooctanoic acid (PFOA) substitute, which is supposedly less accumulative and toxic than PFOA. However, 6:2 FTCA is structurally similar to PFOA, and there had already been reports about its tox
Externí odkaz:
https://doaj.org/article/4adea22064114fc89e6c1accd74282c7
Autor:
Xin Peng, Xin Huang, Shaolu Zhang, Naixin Zhang, Shengfan Huang, Yingying Wang, Zhenxing Zhong, Shan Zhu, Haiwang Gao, Zixiang Yu, Xiaotong Yan, Zhennan Tao, Yuxiang Dai, Zhe Zhang, Xi Chen, Feng Wang, Francois X. Claret, Moshe Elkabets, Ning Ji, Yuxu Zhong, Dexin Kong
Publikováno v:
Advanced Science, Vol 11, Iss 30, Pp n/a-n/a (2024)
Abstract PARP inhibitors (PARPi) hold substantial promise in treating glioblastoma (GBM). However, the adverse effects have restricted their broad application. Through unbiased transcriptomic and proteomic sequencing, it is discovered that the BET in
Externí odkaz:
https://doaj.org/article/71a393bc885744d6a1d90f1327dd6a2c
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 271, Iss , Pp 115909- (2024)
Objective: The effects of air pollution on metabolism have become a popular research topic, and a large number of studies had confirmed that air pollution exposure could induce insulin resistance (IR) to varying degrees, but the results were inconsis
Externí odkaz:
https://doaj.org/article/88dce7724e814e87ba41ec9ab6523474
Autor:
Qixuan Dong, Yajie Guo, Junhua Yuan, Shuping Zhong, Hao Ni, Jingyi Liu, Mengzhen Zhang, Jiaqi Sun, Shuqi Yuan, Huan Yu, Yuxu Zhong, Qixiao Jiang
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 253, Iss , Pp 114671- (2023)
Hexafluoropropylene oxide tetramer acid (HFPO-TeA) is an emerging environmental contaminant, with environmental presence but limited toxicological information. To investigate its potential developmental toxicities, various doses of HFPO-TeA exposure
Externí odkaz:
https://doaj.org/article/45a03e18e37d418b83285b5f42b079a2
Autor:
Xin Peng, Shaolu Zhang, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang, Yuxu Zhong, Zhe-Sheng Chen, Dexin Kong
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-21 (2021)
Abstract Background The critical role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biology has prompted massive efforts to develop PI3K inhibitors (PI3Kis) for cancer therapy. However, recent results from clinical trials have shown on
Externí odkaz:
https://doaj.org/article/46925260bbed4e66aa320b5ae39a76b7
Autor:
Shaolu Zhang, Xin Peng, Xiaofei Li, Hongyan Liu, Baoquan Zhao, Moshe Elkabets, Yao Liu, Wei Wang, Ran Wang, Yuxu Zhong, Dexin Kong
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-14 (2021)
Abstract PARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”. However, glioblastoma (GBM) patients have gained little benefit from PARP inhibito
Externí odkaz:
https://doaj.org/article/53e182bd232544fc958490ff9d0bc68e
Publikováno v:
Molecules, Vol 27, Iss 19, p 6211 (2022)
PI3Kδ is a key mediator of B-cell receptor signaling and plays an important role in the pathogenesis of certain hematological malignancies, such as chronic lymphocytic leukemia. Idelalisib, which targets PI3Kδ specifically, is the first approved PI
Externí odkaz:
https://doaj.org/article/02b99710397340b29bf8f2fa8b67ed0e
Autor:
Zhengming Wang, Yingying Wang, Shan Zhu, Yao Liu, Xin Peng, Shaolu Zhang, Zhe Zhang, Yuling Qiu, Meihua Jin, Ran Wang, Yuxu Zhong, Dexin Kong
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/a48e0341c5994d3898e82d9b3c25f64c
Autor:
Yingying Wang, Qian Ma, Shaolu Zhang, Hongyan Liu, Baoquan Zhao, Bo Du, Wei Wang, Peng Lin, Zhe Zhang, Yuxu Zhong, Dexin Kong
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Digoxin is widely used to treat heart failure. Epidemiological studies suggested it might be used as an anticancer drug or sensitizing agent for cancer therapy. Adriamycin is a well-known anticancer drug, but often causes cardiotoxicity which limits
Externí odkaz:
https://doaj.org/article/db42496d20794cd9af1f20fbec6c37ec
Autor:
Xin Peng, Shaolu Zhang, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang, Yuxu Zhong, Zhe-Sheng Chen, Dexin Kong
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/fb6d18d3a09747a7b71d38fec22e951d